New Two-Pronged cell therapy aims to outsmart tough blood cancers
NCT ID NCT04162353
Summary
This early-phase study is testing the safety of a new type of CAR T-cell therapy called BCMA-CD19 cCAR in patients with advanced multiple myeloma or plasmacytoid lymphoma who have no other treatment options left. The therapy uses a patient's own modified immune cells to attack cancer by targeting two different proteins (BCMA and CD19) on cancer cells, hoping to be more effective and prevent the cancer from escaping treatment. The main goal is to see how safe and tolerable this new approach is in a small group of 12 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chengdu Military General Hospital
RECRUITINGChengdu, Sichuan, China
Contact Email: •••••@•••••
-
Peking University Shenzhen Hospital, China
RECRUITINGShenzhen, Guangdong, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.